Key result
AVR achieves uneventful 2-year outcomes in a patient with multiple myeloma and cardiac amyloidosis.
Why the study?
Patients with malignant hematological disorders may be at an increased risk when undergoing cardiac surgery.
Case Report (n=1)
No
Aortic valve replacement can be safely performed and may improve quality of life in highly selected patients with severe aortic stenosis, cardiac amyloidosis, and multiple myeloma in complete remission.
Answers are grounded in this paper and cite their sources.
AVR may be safely performed in highly selected patients with cardiac amyloidosis and multiple myeloma in remission; extends limited data but remains hypothesis-generating.
Patients suffering from malignant hematological disorders may be at an increased risk when undergoing cardiac surgery. A case of a 67-year-old man with multiple myeloma and cardiac amyloidosis, who underwent aortic valve replacement for severe aortic stenosis, is reported. The patient's postoperative course was uneventful, and he was discharged 16 days after surgery. Currently, two years after surgery, he continues to visit the hospital for dialysis and maintenance therapy without recurrence or exacerbation of multiple myeloma.
No takes yet. Share an insight, caveat, or question.
Masanori et al. (2017) conducted a case report in Multiple myeloma, cardiac amyloidosis, and severe aortic stenosis (n=1). Aortic valve replacement was evaluated. Aortic valve replacement was successfully performed in a 67-year-old man with multiple myeloma and cardiac amyloidosis, with an uneventful postoperative course and no recurrence at two years.
Synapse has enriched 10 related papers. Consider them for comparative context: